Mawer Investment Management Ltd. Sells 1,658 Shares of Moderna, Inc. (NASDAQ:MRNA)

Mawer Investment Management Ltd. decreased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 0.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,901,668 shares of the company’s stock after selling 1,658 shares during the period. Mawer Investment Management Ltd.’s holdings in Moderna were worth $127,088,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Avantax Advisory Services Inc. boosted its position in Moderna by 53.3% in the first quarter. Avantax Advisory Services Inc. now owns 5,035 shares of the company’s stock worth $537,000 after purchasing an additional 1,750 shares during the last quarter. O Shaughnessy Asset Management LLC raised its stake in shares of Moderna by 40.8% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 10,869 shares of the company’s stock valued at $1,158,000 after purchasing an additional 3,148 shares during the period. UniSuper Management Pty Ltd increased its position in shares of Moderna by 307.7% during the 1st quarter. UniSuper Management Pty Ltd now owns 13,158 shares of the company’s stock valued at $1,402,000 after purchasing an additional 9,931 shares during the last quarter. Bessemer Group Inc. increased its position in shares of Moderna by 4.0% during the 1st quarter. Bessemer Group Inc. now owns 7,258 shares of the company’s stock valued at $774,000 after purchasing an additional 276 shares during the last quarter. Finally, Lake Street Advisors Group LLC bought a new position in shares of Moderna during the 1st quarter valued at about $398,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 price objective on shares of Moderna in a research report on Thursday, September 19th. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research report on Monday. Piper Sandler dropped their target price on Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, September 13th. Sanford C. Bernstein started coverage on Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price for the company. Finally, Oppenheimer cut Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $88.89.

Insider Transactions at Moderna

In other Moderna news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. This represents a 13.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last three months, insiders sold 2,930 shares of company stock valued at $217,170. Insiders own 15.70% of the company’s stock.

Moderna Trading Up 0.9 %

Shares of NASDAQ MRNA traded up $0.32 during midday trading on Monday, reaching $37.17. 574,592 shares of the stock were exchanged, compared to its average volume of 4,691,882. The company has a 50 day simple moving average of $58.56 and a 200 day simple moving average of $96.68. The stock has a market capitalization of $14.30 billion, a P/E ratio of -6.45 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the firm earned ($1.39) EPS. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, equities analysts expect that Moderna, Inc. will post -9.43 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.